HTMC0658 tablets for chronic sinus inflammation without nasal polyps
Tests HTMC0658 tablets in adults with chronic rhinosinusitis without nasal polyps.
Key facts
- Who runs it
- Shanghai Yidian Pharmaceutical Technology Development Co., Ltd.
- Where
- China1 site in 1 countryChoose a country to see its sites
- Trial code
- Registry title
- A Study to Evaluate the Efficacy and Safety of HTMC0658 Tablets in the Treatment of Chronic Rhinosinusitis Without Nasal Polyps
- Status
- Recruiting
- Phase
- Phase 2
- People taking part
- 30 people, planned
- Started
- 18 Aug 2025
- Planned end
- Jun 2026
- Type of study
- Interventional
- Treatments tested
- HTMC0658
- Record updated
- 19 September 2025
Who can take part
The trial is looking for adults with long-lasting sinus inflammation without nasal polyps (CRSsNP). Their symptoms continue despite mometasone furoate nasal spray.
- Age
- 18 to 75 years
- Sex
- All sexes
- Disease stage
- Chronic rhinosinusitis without nasal polyps for more than 12 weeks, in both sides of the nose and sinuses on endoscopy or CT scan. Each side must have at least one sinus scoring ≥ 1 point on the Lund-MacKay scale. Nasal Congestion Score ≥ 2 points, Composite Symptom Score ≥ 5 points, SNOT-22 score ≥ 20 points. BMI of at least 18.5. Asthma or COPD must have been stable for 3 months.
- Earlier treatment
- People must have used a stable daily dose of mometasone furoate nasal spray (MFNS) for at least 4 weeks. People cannot join if they had nasal surgery within 4 weeks, or need steroid pills or injections as ongoing treatment. Strong CYP3A4 or CYP2D6 inhibitors or inducers are not allowed within 14 days. Drugs such as tumor necrosis factor-α antagonists are not allowed within 4 weeks.
- Main reasons for not taking part
- Nasal polyps now or in the past
- Cystic fibrosis, primary ciliary dyskinesia, fungal or tooth-related sinus infection, or nasal tumor
- Gum disease (gingivitis/periodontitis) or thickened skin on palms and soles
- Positive test for hepatitis B, hepatitis C, HIV or syphilis
- Current smokers, and pregnant or breastfeeding women
Show the full registry criteria (32)Hide the full registry criteria
Who can take part
- Subjects aged between 18 and 75 years, inclusive, of either sex
- Body Mass Index (BMI) calculated as weight in kilograms divided by the square of height in meters (kg/m²), with a BMI of at least 18.5
- Subjects must meet the diagnostic criteria for chronic rhinosinusitis as defined in the "Chinese Chronic Rhinosinusitis Diagnosis and Treatment Guidelines (2024)," with a disease duration exceeding 12 weeks
- During the screening period, nasal endoscopy must reveal bilateral pathological changes in the nasal mucosa, such as edema and purulent discharge, or a CT scan must show bilateral sinus involvement
- During the screening period, a CT scan must demonstrate bilateral sinus involvement, with at least one sinus on each side scoring ≥ 1 point on the Lund-MacKay (LMK) scale
- During the screening period, the Nasal Congestion Score (NCS) must be ≥ 2 points
- During the screening period, the Composite Symptom Score (CSS) for nasal congestion, rhinorrhea, and facial pain/pressure must be ≥ 5 points
- During the screening period, the Sino-Nasal Outcome Test-22 (SNOT-22) total score must be ≥ 20 points
- Subjects must have been on a stable daily dose of mometasone furoate nasal spray (MFNS) for at least 4 weeks prior to enrollment
- Subjects with asthma or chronic obstructive pulmonary disease (COPD) must have had stable conditions without exacerbations in the 3 months prior to screening (e.g., no emergency room visits, hospitalizations, or systemic corticosteroid use). The use of inhaled corticosteroids must have been at a stable dose, with continuous use for at least 3 months prior to screening, and planned continuation throughout the study period
- Subjects must fully understand the purpose, nature, methodology, and potential adverse events of the trial, voluntarily participate in the trial, and provide written informed consent, or have an authorized legal representative provide informed consent
Who cannot take part
- Requirement for systemic corticosteroids as maintenance therapy during the screening period
- Undergone nasal surgery within 4 weeks prior to screening, or scheduled for sinus surgery during the study period
- Presence of a disease or comorbidity that would interfere with the assessment of the primary efficacy endpoints (e.g., subjects with seasonal allergic rhinitis whose symptoms coincide with the study treatment period; subjects with moderate to severe atopic dermatitis requiring treatment with potent topical corticosteroids, topical calcineurin inhibitors, or biologics; subjects with acute upper respiratory tract infection that, in the investigator's judgment, would affect nasal symptom scoring)
- Presence of an acute infection requiring antibiotic treatment within 4 weeks prior to screening
- Receipt of drugs that may cause skin hyperkeratosis (e.g., tumor necrosis factor-α antagonists) within 4 weeks prior to screening
- Patients who have used strong CYP3A4 or CYP2D6 inhibitors or inducers within 14 days prior to the first administration of the investigational medicinal product
- Subjects who have participated in other drug or medical device trials within 3 months prior to the start of this trial or are currently enrolled in another clinical trial
- Presence of nasal polyps confirmed by nasal endoscopy during the screening period, or a history of nasal polyps
- Inflammatory or autoimmune diseases requiring systemic biologic therapy or immunosuppressive agents (including but not limited to immunodeficiency diseases)
- Known allergy or intolerance to any component of the investigational medicinal product or background therapy
- Subjects with a past or current diagnosis of periodontitis or palmoplantar keratoderma due to functional deficiency of dipeptidyl peptidase 1 (DPP1), or the presence of the following at screening:a. Subjects with current signs of gingivitis/periodontitis.b. Subjects with a history of palmoplantar keratoderma or erythema
- Subjects with positive test results for hepatitis B surface antigen, hepatitis C virus antibody, human immunodeficiency virus antibody, and/or syphilis serology during the screening period
- Subjects with elevated liver function test results during the screening period and currently requiring treatment for liver disease. Elevated liver function tests are defined as: aspartate aminotransferase (AST) or alanine aminotransferase (ALT) > 2.0 × upper limit of normal (ULN), or total bilirubin (TBIL) > 1.5 × ULN
- Diagnosis of cystic fibrosis (CF) or primary ciliary dyskinesia
- Presence of significant craniofacial structural abnormalities or severe nasal septal deviation
- Radiological suspicion or confirmed diagnosis of invasive fungal rhinosinusitis, odontogenic sinusitis, osteoma, or nasal tumor
- Current smokers (defined as adults who have smoked at least 100 cigarettes in their lifetime and are currently smoking) or those who cannot abstain from smoking during the trial
- Male subjects who plan to donate sperm or have a fathering plan from the start of dosing until 90 days after the last dose and are unwilling to use effective non-pharmacological contraceptive measures
- Female subjects who plan to donate oocytes or have a pregnancy plan from the start of dosing until 30 days after the last dose and are unwilling to use effective non-pharmacological contraceptive measures
- Pregnant or breastfeeding women
- Subjects whom the investigator deems unsuitable for participation in this study for any reason
Eligibility questionnaire
From the criteria published for this trial, to help you prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.
- Age
- Chronic sinusitis without nasal polyps
This trial is currently available in China.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
The purpose of this clinical trial is to assess the efficacy and safety of HTMC0658 tablets in treating subjects with chronic rhinosinusitis without nasal polyps (CRSsNP).
The group in the trial
- HTMC0658Treatment being tested
Participants will receive HTMC0658 tablet, orally, QD for 12 weeks along with mometasone furoate nasal spray (MFNS) by nasal route as background therapy at a stable dose according to the Investigator's discretion and local guidance.
Next steps
For your doctor
Doctor ask sheet
A PDF for your doctor: what this trial tests, who can take part, and 2 eligibility questions with room for answers and notes.
PDF, US Letter, 1 to 2 pages. A4 size
For the study team
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- A Phase IIa Clinical Study to Evaluate the Efficacy and Safety of HTMC0658 Tablets in the Treatment of Chronic Rhinosinusitis Without Nasal Polyps
- Plain-language title
- HTMC0658 tablets for chronic sinus inflammation without nasal polypsGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 15 November 2026.
- Criteria questions
- Built from NCT07174115, who can take part
- Record updated
- 19 September 2025